NovoCure opened lower at $11.84, compared with its previous close of $11.99. In the last trading session, the stock traded between $11.63 and $12.11. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in NovoCure is now worth
$ 10.49
Resulting in a loss of
$ 89.51 (89.51%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.28 (-2.29%)
Day High
$12.11
Day Low
$11.63
Day Open
$11.84
Prev Close
$11.99
Volume
9,83,307
1W Return
-19.69%
1M Return
-20.53%
3M Return
-33.79%
6M Return
-35.28%
1Y Return
-1.22%
Fundamentals
Market Cap ($ Mn)
1,370
PE Ratio
-
PB Ratio
6.14
PEG Ratio
-
ROE
-38.85%
ROCE
-24.90%
EPS (TTM)
$-0.09
Investment Returns
1 Week
-19.69%
1 Month
-20.53%
3 Months
-33.79%
6 Months
-35.28%
9 Months
11.57%
Financials
Quarterly
All values in $ Mn
158.8
Jun 25
167.2
Sep 25
174.3
Dec 25
174.1
Mar 26
183.6
Jun 26
193.4
Sep 26
Updates
11Nov
Ladenburg Thalmann maintains buy on NovoCure, lifts price target to $31
Ladenburg Thalmann maintains a Buy rating on NovoCure. Price target raised from $27 to $31. Analyst Kevin DeGeeter issued the updated recommendation.
2 days ago
9Nov
Novocure stock slips after FDA rejects Optune Mya approval
Novocure shares dropped 1.84% to $13.04 following FDA rejection of Optune Mya. FDA cited uncertainty in clinical benefit as reason for Not Approvable Letter. Q3 revenue rose 16% YoY to $193.4 million, beating consensus estimates. FY26 sales guidance raised to $736 million-$743 million from previous range.
3 days ago
30Oct
Wells Fargo lowers NovoCure price target to $15, maintains equal-weight
Wells Fargo lowered NovoCure's price target from $20 to $15. Analyst Larry Biegelsen maintained an Equal-Weight rating. The revision reflects updated valuation assumptions for the company.
13 days ago
30Oct
Evercore ISI maintains Outperform on NovoCure, cuts price target to $20
Evercore ISI Group maintains an Outperform rating on NovoCure. Price target lowered from $23 to $20 by analyst Vijay Kumar. Rating action reflects continued bullish stance on long-term prospects.
13 days ago
29Oct
NovoCure Q3FY26 Results: Revenue up 16%, raises full-year guidance
Raised FY26 net revenue guidance to $736-743 million (12-13% growth). Q3 net revenue hit record $193 million, up 16% YoY, beating estimates. Adjusted EBITDA turned positive at $16 million; FY26 guidance raised to $24-34 million. Net loss narrowed to $0.09 per share, significantly beating consensus of $(0.24). Gross margin expanded to 77% from 73% YoY due to supply chain efficiencies.
14 days ago
29Oct
NovoCure raises FY26 sales guidance to $736M-$743M, beats estimates
NovoCure raises FY2026 sales guidance to $736.000 million-$743.000 million. New lower bound exceeds previous upper bound of $725.000 million. Updated range surpasses analyst estimate of $725.814 million.
